Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA)

PHASE2CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

December 28, 2016

Primary Completion Date

February 28, 2019

Study Completion Date

August 31, 2019

Conditions
Mild-moderate Alzheimer's Disease
Interventions
DRUG

Donepezil

5mg or 10mg, once a day, 24 weeks

DRUG

DHP1401

Total 500mg or 1,000mg was administrated in two divided doses a day for 24 weeks

DRUG

Placebo

Placebo was administrated in two divided dosed a day for 24 weeks

Trial Locations (16)

35233

Daejeon Eulji Medical Center, Daejeon

Unknown

The Catholic University of Korea, Bucheon, ST. Mary's Hospital, Bucheon-si

Myongji Hospital, Goyang-si

Seoul National University Bundang Hospital, Seongnam-si

Ajou University Medical Center, Suwon

Chonnam National University Hospital, Gwangju-si

Dong-A University Hospital, Busan

Yeungnam University Medical Center, Daegu

Hanyang University Guri Hospital, Guri-si

Gachon University Gil Medical Center, Incheon

Inha University Hospital, Incheon

Hanyang University Medical Center, Seoul

Konkuk University Hospital, Seoul

Korea University Anam Hospital, Seoul

The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul

06973

Chung-ang University Hospital, Seoul

All Listed Sponsors
lead

Daehwa Pharmaceutical Co., Ltd.

INDUSTRY

NCT03055741 - Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA) | Biotech Hunter | Biotech Hunter